SG11201707521QA - Nk-3 receptor antagonists for therapeutic or cosmetic treatment of excess body fat - Google Patents
Nk-3 receptor antagonists for therapeutic or cosmetic treatment of excess body fatInfo
- Publication number
- SG11201707521QA SG11201707521QA SG11201707521QA SG11201707521QA SG11201707521QA SG 11201707521Q A SG11201707521Q A SG 11201707521QA SG 11201707521Q A SG11201707521Q A SG 11201707521QA SG 11201707521Q A SG11201707521Q A SG 11201707521QA SG 11201707521Q A SG11201707521Q A SG 11201707521QA
- Authority
- SG
- Singapore
- Prior art keywords
- therapeutic
- receptor antagonists
- body fat
- cosmetic treatment
- excess body
- Prior art date
Links
- 102000002003 Neurokinin-3 Receptors Human genes 0.000 title 1
- 108010040716 Neurokinin-3 Receptors Proteins 0.000 title 1
- 210000000577 adipose tissue Anatomy 0.000 title 1
- 239000002537 cosmetic Substances 0.000 title 1
- 239000002464 receptor antagonist Substances 0.000 title 1
- 229940044551 receptor antagonist Drugs 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Child & Adolescent Psychology (AREA)
- Obesity (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Cosmetics (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15159296 | 2015-03-16 | ||
| EP15193513 | 2015-11-06 | ||
| PCT/EP2016/055735 WO2016146712A1 (en) | 2015-03-16 | 2016-03-16 | Nk-3 receptor antagonists for therapeutic or cosmetic treatment of excess body fat |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201707521QA true SG11201707521QA (en) | 2017-10-30 |
Family
ID=55538244
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201707521QA SG11201707521QA (en) | 2015-03-16 | 2016-03-16 | Nk-3 receptor antagonists for therapeutic or cosmetic treatment of excess body fat |
Country Status (23)
| Country | Link |
|---|---|
| US (3) | US10624890B2 (en) |
| EP (1) | EP3271015B8 (en) |
| JP (1) | JP6762312B2 (en) |
| KR (2) | KR20240033207A (en) |
| CN (1) | CN107405347B (en) |
| AU (1) | AU2016232191B2 (en) |
| BR (1) | BR112017019829A2 (en) |
| CA (1) | CA2977444A1 (en) |
| DK (1) | DK3271015T3 (en) |
| EA (1) | EA036709B1 (en) |
| ES (1) | ES2965675T3 (en) |
| FI (1) | FI3271015T3 (en) |
| HR (1) | HRP20231661T1 (en) |
| HU (1) | HUE064813T2 (en) |
| IL (1) | IL254386B (en) |
| LT (1) | LT3271015T (en) |
| MX (1) | MX2017011937A (en) |
| NZ (2) | NZ773981A (en) |
| PL (1) | PL3271015T3 (en) |
| RS (1) | RS65039B1 (en) |
| SG (1) | SG11201707521QA (en) |
| SI (1) | SI3271015T1 (en) |
| WO (1) | WO2016146712A1 (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20210401821A1 (en) * | 2018-11-15 | 2021-12-30 | Kyushu University, National University Corporation | Prophylactic or therapeutic agent and medicinal composition for il-31-mediated disease |
| CN112272670B (en) * | 2019-04-16 | 2023-12-12 | 上海翰森生物医药科技有限公司 | Di-ring derivative-containing inhibitor, preparation method and application thereof |
| AU2022263070A1 (en) * | 2021-04-21 | 2023-10-26 | Changchun Genescience Pharmaceutical Co., Ltd. | Imidazole-containing condensed ring derivative, preparation method therefor, and application thereof in medicine |
| CN116650495B (en) * | 2021-12-10 | 2024-04-19 | 中南大学湘雅医院 | Application of aromatic compound as activator of nervous Cong Su protein-B2 in preparation of medicine for treating osteoporosis |
| WO2023147134A2 (en) * | 2022-01-31 | 2023-08-03 | Acer Therapeutics, Inc. | Methods for treating patients having low estrogen with nk3 antagonists |
| WO2024083150A1 (en) * | 2022-10-19 | 2024-04-25 | 长春金赛药业有限责任公司 | Crystal form of nk3r antagonist, and preparation method therefor and use thereof |
| WO2024083164A1 (en) * | 2022-10-21 | 2024-04-25 | 长春金赛药业有限责任公司 | Solvate of indoline spiro compound, and crystal form thereof, preparation method therefor and use thereof |
| WO2024083160A1 (en) * | 2022-10-21 | 2024-04-25 | 长春金赛药业有限责任公司 | Crystal form and amorphous substance of indoline spiro compound, and preparation method therefor and use thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008131779A1 (en) * | 2007-04-26 | 2008-11-06 | H. Lundbeck A/S | Isoquinolinone derivatives as nk3 antagonists |
| EA023161B1 (en) | 2010-04-02 | 2016-04-29 | Евроскрин С.А. | Triazolopyrazine compounds as nk3 receptor selective antagonists, pharmaceutical composition and methods for use in nk3 receptors mediated disorders |
| US10065960B2 (en) | 2010-04-02 | 2018-09-04 | Ogeda Sa | NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders |
| SI2763992T1 (en) | 2011-10-03 | 2016-08-31 | Euroscreen S.A. | Novel chiral n-acyl-5,6,7,(8-substituted)-tetrahydro-(1,2,4)triazolo(4,3-a)pyrazines as selective nk-3 receptor antagonists, pharmaceutical composition, and methods for use in nk-3 receptor mediated disorders |
| EP2948455B1 (en) * | 2013-03-29 | 2017-09-27 | Ogeda S.A. | N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro- [1,2,4]triazolo[4,3-a]pyrazines as selective nk-3 receptor antagonists, pharmaceutical composition, methods for use in nk-3 receptor-mediated disorders |
| EP2978766B1 (en) | 2013-03-29 | 2018-12-19 | Ogeda Sa | N-acyl-(3-substituted)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines as selective nk-3 receptor antagonists, pharmaceutical composition, methods for use in nk-3 receptor-mediated disorders |
| AU2014242908B2 (en) | 2013-03-29 | 2018-07-19 | Ogeda Sa | Novel N-acyl-(3-substituted)-(8-methyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor-mediated disorders |
| WO2016046398A1 (en) | 2014-09-25 | 2016-03-31 | Euroscreen Sa | Novel chiral synthesis of n-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines |
-
2016
- 2016-03-16 EP EP16710199.7A patent/EP3271015B8/en active Active
- 2016-03-16 SI SI201631784T patent/SI3271015T1/en unknown
- 2016-03-16 ES ES16710199T patent/ES2965675T3/en active Active
- 2016-03-16 US US15/557,832 patent/US10624890B2/en active Active
- 2016-03-16 BR BR112017019829A patent/BR112017019829A2/en not_active Application Discontinuation
- 2016-03-16 MX MX2017011937A patent/MX2017011937A/en unknown
- 2016-03-16 WO PCT/EP2016/055735 patent/WO2016146712A1/en active Application Filing
- 2016-03-16 DK DK16710199.7T patent/DK3271015T3/en active
- 2016-03-16 CA CA2977444A patent/CA2977444A1/en active Pending
- 2016-03-16 JP JP2017546590A patent/JP6762312B2/en active Active
- 2016-03-16 CN CN201680015846.XA patent/CN107405347B/en active Active
- 2016-03-16 FI FIEP16710199.7T patent/FI3271015T3/en active
- 2016-03-16 RS RS20231223A patent/RS65039B1/en unknown
- 2016-03-16 AU AU2016232191A patent/AU2016232191B2/en active Active
- 2016-03-16 EA EA201791901A patent/EA036709B1/en not_active IP Right Cessation
- 2016-03-16 NZ NZ773981A patent/NZ773981A/en unknown
- 2016-03-16 PL PL16710199.7T patent/PL3271015T3/en unknown
- 2016-03-16 HU HUE16710199A patent/HUE064813T2/en unknown
- 2016-03-16 NZ NZ734635A patent/NZ734635A/en unknown
- 2016-03-16 LT LTEPPCT/EP2016/055735T patent/LT3271015T/en unknown
- 2016-03-16 KR KR1020237033062A patent/KR20240033207A/en unknown
- 2016-03-16 HR HRP20231661TT patent/HRP20231661T1/en unknown
- 2016-03-16 SG SG11201707521QA patent/SG11201707521QA/en unknown
- 2016-03-16 KR KR1020177026643A patent/KR20170124566A/en not_active Application Discontinuation
-
2017
- 2017-09-07 IL IL254386A patent/IL254386B/en active IP Right Grant
-
2020
- 2020-02-20 US US16/796,422 patent/US11478472B2/en active Active
-
2022
- 2022-09-13 US US17/943,711 patent/US20230039022A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL254386A0 (en) | Nk-3 receptor antagonists for therapeutic or cosmetic treatment of excess body fat | |
| PL3244819T3 (en) | Device for cosmetic treatment of brown skin spots by cryogenesis | |
| PT3212233T (en) | Combination therapy for treatment of disease | |
| IL270752B (en) | Pyrrolopyridine-aniline compounds for treatment of dermal disorders | |
| IL262852A (en) | Treatment of complement-mediated disorders | |
| IL281089A (en) | Lingo-1 antagonists and uses for treatment of demyelinating disorders | |
| IL265181A (en) | Apparatus for massaging human breast | |
| HK1258128A1 (en) | Selection of patients for combination therapy | |
| HK1249865B (en) | Treatment of pain | |
| GB201612043D0 (en) | Composition for treatment of disorders | |
| GB201611413D0 (en) | Method of skin care | |
| HK1247884A1 (en) | Method for cosmetic treatment of the skin | |
| IL266243A (en) | Use of senicapoc for treatment of neuropathic pain | |
| GB201607388D0 (en) | Treatment of impulsivity-related disorders | |
| ZA201807692B (en) | New use of product for skin treatment | |
| EP3621619C0 (en) | Compounds and methods for treatment of visceral pain | |
| IL234962A0 (en) | Use of agents for treating fat-related disorders | |
| PT3271015T (en) | Nk-3 receptor antagonists for therapeutic or cosmetic treatment of excess body fat | |
| GB201604359D0 (en) | Treatment of tissue disorders | |
| IL274132A (en) | Treatment of skin disorders | |
| EP3638223C0 (en) | Bromhexine for the treatment of pain | |
| GB201706823D0 (en) | Treatment of psychological disorders | |
| GB201621398D0 (en) | Treatment of emt-associated disease | |
| GB201504144D0 (en) | Treatment of Parkinson's disease | |
| GB201412313D0 (en) | Treament of human or animal body surfaces |